NEW YORK (GenomeWeb) – GenomeDx Biosciences announced today that it has signed an exclusive deal with Medison Pharma to distribute its Decipher Prostate Cancer Classifier in Israel and the Palestinian Authority.

Specific terms of the arrangement were not disclosed.

Decipher is a genomic, RNA expression-based test that predicts cancer aggressiveness with an assay of 22 validated biomarkers associated with metastatic disease. Developed by GenomeDx in collaboration with the Mayo Clinic, the test was first launched in the US in 2013.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.